

JANUARY 24, 2024 • VIRTUAL

# Fundamentals and Advances in **Immunotherapy** in the **Oncology Patient**

for the Advanced Practice Provider



Memorial Sloan Kettering  
Cancer Center

# Overview

**Immunotherapeutics has changed the landscape of treatment modalities available to the cancer patient in both solid tumor and hematologic malignancies. Since the breakthrough of ipilimumab, there have been fast-paced and ongoing advancements in the field of immunotherapy, revolutionizing clinical management at a rapid pace.**

This one-day virtual symposium will review fundamental concepts and recent advances in immunotherapy designed to meet the learning needs of advanced practice providers (APPs) and other allied health professionals. Clinical application in solid tumor and hematologic malignancies will be discussed as well as toxicity management, including immune-related adverse events resulting from immune checkpoint inhibition.

Experts will discuss the fundamentals of immune checkpoint blockade and CAR T cell therapy, as well as advancements in TIL and BITE therapy, novel combination therapy, and algorithmic management of immune-related adverse events. Toxicity management will be communicated through case study applications and demonstration of common, rare, and severe immune-related adverse events.

The overall goal of this program is to improve cancer patient outcomes by advancing the science, development, and application of cancer immunology and immunotherapy through fundamental understanding and clinical application.

## TARGET AUDIENCE

The target audience for this program includes nurse practitioners, physician assistants, certified registered nurse anesthetists, physicians, and nurses who care for oncology patients. We are pleased to offer **complimentary registration for nursing students and registrants residing in low and lower-middle income countries.**

This symposium is set to be an **exclusively live virtual experience.** Detailed Zoom access and participation instructions will be provided to registrants prior to the start of the program.

## LEARNING OBJECTIVES

At the conclusion of this symposium, learners will be able to:

- Describe the principles surrounding the immunity cycle
- Explain fundamental principles of immunotherapeutic agents including immune checkpoint inhibition, CAR T cell, TIL, and BITE therapies.
- Discuss clinical application of immune modulated agents in the oncology population
- Discuss the symptoms of Cytokine release Syndrome, ICANS, prolonged cytopenias and clinical management
- Recognize and identify common, rare, and severe immune related adverse events attributed to immune checkpoint inhibition

## ONLINE SYLLABUS

Attendees of this symposium will receive access to a syllabus, which includes select of video recordings of the lectures.

## MSK SYMPOSIUM DIRECTOR



**Mary Kate Kasler, DNP, RN, ACNP-BC**  
Advanced Practice Provider

## MSK SYMPOSIUM CO-DIRECTOR



**Kerry E. Williams, MSN, RN, ANP-BC, AOCNP**  
Advanced Practice Provider

## MSK ADVANCED PRACTICE PROVIDER SPONSOR



**Nicole Zakak, MS, RN, CPNP, CPHON®**  
Advanced Practice Provider Quality and  
Professional Development Director

## MSK PHYSICIAN SPONSOR



**Sandra P. D'Angelo, MD**  
Associate Attending

Memorial Sloan Kettering Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.

## MSK PLANNING COMMITTEE

**Linda D'Andrea, MSN, RN, PPCNP, CPHON®**

Advanced Practice Provider Specialist

**Kelly Haviland, PhD, RN, MSN, FNP-BC, TGNB-C**

Advanced Practice Provider Manager

LGBTQI+ Clinical Consultant

**Yelena Shames, MSN, RN, ACNP-BC, CNRN**

Nurse Leader, Clinical Trials

**Kristen Stasi, MSN, RN, OCN**

Clinical Trials Nurse

**Caroll Tipian, DNP, AGACNP-BC**

Advanced Practice Provider

**Joanne Wells, MSN, RN, ANP-BC, AOCNP**

Advanced Practice Provider

## INVITED FACULTY



**Anne R. Bass, MD**

Attending Physician,  
Hospital for Special Surgery  
Professor of Clinical Medicine,  
Weill Cornell Medicine

## MSK FACULTY

**Ashley Ames, MSN, RN, AGPCNP-BC**

Advanced Practice Provider

**Lauren Banks, MD, PhD**

Assistant Attending

**Cameron Brennan, MD**  
Attending

**Claudia Calderon, MSN, AGPCNP-BC, OCN**  
Advanced Practice Provider

**Angela Chan, DNP, AGPCNP-BC, RN, OCN**  
Advanced Practice Provider

**Ruben Diaz, DNP, FNP-BC, BC-ADM, CDCES**  
Advanced Practice Provider

**Stephanie Incardona, MSN, AGACNP-BC**  
Advanced Practice Provider

**Liubou Korzun, MS, PA-C**  
Advanced Practice Provider

**Alexander Lesokhin, MD, PhD**  
Associate Attending

**Alina Markova, MD**  
Associate Attending

**Alison Massey Tanner, MSN, RN, ANP-BC**  
Advanced Practice Provider

**Katherine Nagel, MSN, FNP-BC**  
Advanced Practice Provider

**Jaclyn Newfield, FNP-BC**  
Advanced Practice Provider

**Katy Nickolaus, MS, PA-C**  
Advanced Practice Provider

**Alexander Shoushtari, MD**  
Assistant Attending

**James W. Smithy MD, MHS**  
Assistant Attending

# Schedule

WEDNESDAY, JANUARY 24, 2024

8:00 AM — 5:15 PM EST

7:55 AM Attendee Zoom Sign On

8:00 AM **Welcome and Introduction**  
Mary Kate Kasler, DNP, RN, ACNP-BC

8:05 AM **Opening Remarks**  
Sandra P. D'Angelo, MD

## Fundamentals of Immunotherapy

MODERATOR: Mary Kate Kasler, DNP, RN, ACNP-BC

8:10 AM **Mechanism of Action of Checkpoint Blockade With a Focus on PD1, PDL1, and CTLA-4**  
James W. Smithy MD, MHS

8:40 AM **Novel Checkpoint Inhibitors and Combination Therapy in the Clinical Setting**  
James W. Smithy MD, MHS

9:00 AM **Discussion**

## Clinical Application of Immune Checkpoint Inhibitors in Solid Tumor Malignancy

MODERATOR: Joanne Wells, MSN, RN, ANP-BC, AOCNP

9:10 AM **Neoadjuvant Combination Modalities in Resectable Non Small Cell Lung Cancer**  
Alison Massey Tanner, MSN, RN, ANP-BC

9:30 AM **Novel Immune Modulated Agents in the Treatment of Glioblastoma**  
Cameron Brennan, MD

9:50 AM **Clinical Landscape of Immunotherapy in Soft Tissue Sarcoma: Fundamentals and Advances in Immunotherapy**  
Lauren Banks, MD, PhD

10:10 AM **Panel Discussion**

10:25 AM Break

## Clinical Updates in Solid Tumor and Novel Immune Modulation

MODERATOR: Kristen Stasi, MSN, RN, OCN

- 10:35 AM **Benefit of Adjuvant Combination Therapy vs. Surveillance in High Risk Hepatocellular Carcinoma Patients**  
Claudia Calderon, MSN, AGPCNP-BC, OCN
- 10:55 AM **Overall Survival (OS) in Recurrent or Metastatic Cervical Cancer Using Combination Therapy**  
Katy Nickolaus, MS, PA-C
- 11:15 AM **Panel Discussion**
- 11:35 AM Lunch Break

## Fundamentals of T Cell Therapy

MODERATOR: Yelena Shames, MSN, RN, ACNP-BC, CNRN

- 12:15 PM **Fundamentals of Chimeric Antigen Receptor (CAR) T Cell Immunotherapy**  
Katherine Nagel, MSN, FNP-BC  
Angela Chan, DNP, AGPCNP-BC, RN, OCN
- 12:35 PM **Implementation of Cellular Therapy in the Solid Tumor Population: The Use of TIL Therapy in Melanoma**  
Alexander Shoushtari, MD
- 1:05 PM **Panel Discussion**

## Clinical Application of Immune Therapy in Hematologic Malignancy

MODERATOR: Caroll Tipian, DNP, AGACNP-BC

- 1:20 PM **Immunotherapy and CAR T Cell Therapy in Hematologic Malignancies Lymphoma**  
Ashley Ames, MSN, RN, AGPCNP-BC
- 1:50 PM **FDA Approved CAR T Products in the Treatment and Management of Leukemia**  
Stephanie Incardona, MSN, AGACNP-BC
- 2:10 PM **T Cell Re-Directing Therapy in Multiple Myeloma**  
Alexander Lesokhin, MD, PhD
- 2:40 PM **Panel Discussion**
- 2:55 PM Break



## Diagnosis and Clinical Management of Immune Related Adverse Events (irAE)

MODERATOR: Kerry E. Williams, MSN, RN, ANP-BC, AOCNP

- 3:05 PM      **Pneumonitis**  
Liubou Korzun, MS, PA-C
- 3:20 PM      **Immunotherapy Induced Diabetes Mellitus**  
Ruben Diaz, DNP, FNP-BC, BC-ADM, CDCES
- 3:40 PM      **Arthralgias and Myalgias**  
Anne R. Bass, MD
- 4:00 PM      **Hepatotoxicity**  
Jaclyn Newfield, FNP-BC
- 4:20 PM      **Dermatologic irAEs**  
Alina Markova, MD
- 4:40 PM      **Overview of Adverse Events in the Cellular Therapy Patient:  
CRS, ICANS, and Prolonged Cytopenias**  
Caroll Tipian, DNP, AGACNP-BC
- 5:00 PM      **Q&A and Panel Discussion**
- 5:15 PM      **Closing Remarks**  
Kerry E. Williams, MSN, RN, ANP-BC, AOCNP
- 5:20 PM      Adjournment

# Accreditation

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

## AMA CREDIT DESIGNATION STATEMENT

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of **8.00 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## ABIM MOC RECOGNITION STATEMENT

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to **8.00 MOC points** in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

## ADVANCED PRACTICE PROVIDERS

**American Academy of Nurse Practitioners National Certification Program** accepts *AMA PRA Category 1 Credits™* from organizations accredited by the ACCME.

**American Nurses Credentialing Center (ANCC)** accepts *AMA PRA Category 1 Credits™* from organizations accredited by the ACCME.

**National Commission on Certification of Physician Assistants (NCCPA)** accepts *AMA PRA Category 1 Credits™* from organizations accredited by ACCME.



Memorial Sloan Kettering  
Cancer Center



---

REGISTER ONLINE AT  
**[msk.org/immunotherapyAPP](https://msk.org/immunotherapyAPP)**

---

#### REGISTRATION FEES

Physicians (MDs, PhDs, and DOs)	\$249
Advanced Practice Providers	\$199
Nursing and Other Healthcare Professionals	\$149
Residents, Fellows, and APP Students	\$25
Industry Professionals*	\$435
Nursing Students and Registrants in Low-and Lower-Middle-Income Countries**	Complimentary
MSK Employees	Complimentary

**\*Industry professionals** may attend MSK CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities.

**Please note that the residents, fellows, and APP students rate is non-refundable.**

#### DISCOUNTS/PROMOTIONS

- **\*\*We are pleased to offer complimentary registration to nursing students and registrants residing in low and lower-middle income countries** as defined by The World Bank. Please visit the Symposium website for additional details.
- **A registration discount is available for MSK Alumni and MSK Cancer Alliance members** to attend this program. Please visit the Symposium website for additional details.

Please visit [msk.org/immunotherapyAPP](https://msk.org/immunotherapyAPP) for additional details, including our cancellation policy.



Memorial Sloan Kettering  
Cancer Center